|Bid||0.00 x 1300|
|Ask||0.00 x 100000|
|Day's Range||3,574.50 - 3,680.00|
|52 Week Range||2,850.60 - 3,680.00|
|PE Ratio (TTM)||332.43|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
The Zacks Analyst Blog Highlights: UnitedHealth, Amgen, United Technologies, CSX and General Dynamics
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab).
THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS® (carfilzomib).
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Results Support Early ...
Amgen Inc (NASDAQ:AMGN), a large-cap worth $134.32B, comes to mind for investors seeking a strong and reliable stock investment. Risk-averse investors who are attracted to diversified streams of revenue andRead More...
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.